NanoString is committed to advancing scientific understanding of the impact of the coronavirus SARs-CoV-2 on human health worldwide. As many of our customers shift their work to addressing urgent needs around therapeutic & vaccine development, and studying viral pathogenesis, we are joining them in this effort.
NanoString offers a broad range of high-plex gene expression panels enabling research on pathogenesis and the host response. In a recently published study, the nCounter® Immunology Panel was used to describe the dynamic and varied immune response that shapes the progression of COVID-19 (Ong et al, Host & Microbe 2020). NanoString is now offering a new COVID-19 Panel Plus product that can be added to any Gene Expression Panel or Custom CodeSet. This enables measurement of the SARS-CoV-2 virus as well as the human or mouse ACE2 receptor RNA as an addition to the measurement of other genes in the assay.
The GeoMx® Digital Spatial Profiler (DSP) enables simultaneous high-plex spatial analysis of pathogens and host response with FFPE and fresh frozen tissue. NanoString is developing a five-antibody custom protein module to be run with our GeoMx DSP protein assays and an ~1,800-plex RNA panel to facilitate spatial studies of the SARs-CoV-2 virus and host response. These assays will include SARs-CoV-2 viral markers and the ACE2 receptor, among other receptors, proteases, cell markers, and viral response markers, and will be available as early as May.
- The COVID-19 Panel Plus is a beta product for experimental Research Use Only (RUO)
- Probes are compatible for use with most nCounter Gene Expression Panels
- The COVID-19 Panel Plus beta cannot be used as an individual assay (as with all Panel Plus products)
If you would like more information on these reagents, please complete the form below.
Learn more about how researchers already use nCounter® gene expression panels to study infectious disease and the host response for applications ranging from basic research to vaccine and therapeutic development.
NanoString is developing protein and RNA assays for the spatial analysis of SARs-CoV-2 infected samples. A five-antibody custom, ready-to-go panel, with receptor, protease, and viral markers will be available in May 2020. This COVID-19 custom panel will be run with the GeoMx Immune Profiling Core with optional modules enabling up to 96-plex spatial studies of SARs-CoV-2 and the host response with readout on the nCounter. The Immune Activation Status Module and the Immune Cell Typing Module will more deeply profile proteins involved in T cell activation markers and well as specialized immune cell types including macrophages and T regs.
The COVID-19 Panel Plus is a beta product for experimental Research Use Only (RUO).